ozanimod vs tamuzimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,5 modulator)
Reliable signal

NCT02435992 · Phase 3 · completed

Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.

Next expected readout: July 2032 · NCT05076175 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)

Result source: NCT02435992

tamuzimod

Developed by Eli Lilly and partners

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P1 receptor modulator)
Reliable signal

NCT05156125 · Phase 2 · terminated

This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.

Reported efficacy

Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)

Result source: NCT05156125

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointozanimodtamuzimod
Clinical remission (induction)18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
27.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125
Clinical remission (maintenance)37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
—Not reported
Clinical response (induction)47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
—Not reported
Endoscopic improvement (induction)27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
—Not reported
Corticosteroid-free remission (maintenance)31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992—Not reported

Clinical remission (induction)

ozanimod
18.4% vs 6%+12.4 vs placebowk 10 · n 429NCT02435992
3 other results
  • 21% vs 6% wk 10 · n 367 · Phase 3 · primary NCT02435992
  • 16.4% vs 6.2% 1 mg · wk 8 · n 67 · Phase 2 · primary NCT01647516
  • 13.8% vs 6.2% 0.5 mg · wk 8 · n 65 · Phase 2 · primary NCT01647516
tamuzimod
27.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125

Clinical remission (maintenance)

ozanimod
37% vs 18.5%+18.5 vs placebowk 52 · n 230NCT02435992
2 other results
  • 20.9% vs 6.2% 1 mg · wk 32 · n 67 · Phase 2 · secondary NCT01647516
  • 26.2% vs 6.2% 0.5 mg · wk 32 · n 65 · Phase 2 · secondary NCT01647516
tamuzimod
—Not reported

Clinical response (induction)

ozanimod
47.8% vs 25.9%+21.9 vs placebowk 10 · n 429NCT02435992
3 other results
  • 52.6% vs 25.9% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 56.7% vs 36.9% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 53.8% vs 36.9% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
tamuzimod
—Not reported

Endoscopic improvement (induction)

ozanimod
27.3% vs 11.6%+15.7 vs placebowk 10 · n 429NCT02435992
3 other results
  • 27.2% vs 11.6% wk 10 · n 367 · Phase 3 · secondary NCT02435992
  • 34.3% vs 12.3% 1 mg · wk 8 · n 67 · Phase 2 · secondary NCT01647516
  • 27.7% vs 12.3% 0.5 mg · wk 8 · n 65 · Phase 2 · secondary NCT01647516
tamuzimod
—Not reported

Corticosteroid-free remission (maintenance)

ozanimod
31.7% vs 16.7%+15 vs placebowk 52 · n 230NCT02435992
tamuzimod
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ozanimod: 4 of 4 rows · tamuzimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricozanimodtamuzimod
Dropout rate
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
11.7%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
46.3%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
69.5%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
4.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
4.3%60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.1%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Discontinued due to AEs
—1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
—1mg
NCT02435992 · Phase 3 · monotherapy
—1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
3.3%RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
7.4%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
6.1%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
3%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
2.9%60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
1.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Serious AEs
4%1mga
NCT02435992 · Phase 3 · monotherapy
show 15 more results
6.3%1mg
NCT02435992 · Phase 3 · monotherapy
5.2%1mg
NCT02435992 · Phase 3 · monotherapy
—RPC1063 (Maintenance Period)
NCT02435992 · Phase 3 · monotherapy
—RPC1063 Cohort 2 (Induction Period
NCT02435992 · Phase 3 · monotherapy
14.8%RPC01-202 Ozanimod Open Label
NCT02531126 · Phase 3 · monotherapy
17.2%RPC01-3101 Ozanimod-Ozanimod
NCT02531126 · Phase 3 · monotherapy
3%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
2.4%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
18.6%1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
1.5%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
0%0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
25%0.5 mg/1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
9.1%Open-Label Treatment Period (OLP):
NCT01647516 · Phase 2 · registry result, not featured evidence
—60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
4.3%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
0%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.2%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
2.7%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
5.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Most frequent reported AEs
1mga
anaemia 3.5% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
show 11 more results
1mg
anaemia 4.1% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
1mg
anaemia 0.9% (placebo 6%)
NCT02435992 · Phase 3 · monotherapy
covid-19 25.9% (placebo 16.8%)
lymphopenia 16.7% (placebo 17.3%)
leukopenia 7.4% (placebo 4.1%)
NCT02531126 · Phase 3 · monotherapy
lymphopenia 16.3% (placebo 17.3%)
covid-19 11.3% (placebo 16.8%)
lymphocyte count decreased 10.8% (placebo 12.8%)
NCT02531126 · Phase 3 · monotherapy
1 mg
alanine aminotransferase increased 3% (placebo 0%)
headache 3% (placebo 4.6%)
anaemia 1.5% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
alanine aminotransferase increased 2.4% (placebo 0%)
colitis ulcerative 2.4% (placebo 1.5%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
1 mg
hypertension 11.9% (placebo 0%)
gamma-glutamyltransferase increased 8.5% (placebo 0%)
upper respiratory tract infection 8.5% (placebo 3.1%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
anaemia 6.2% (placebo 6.2%)
colitis ulcerative 3.1% (placebo 1.5%)
back pain 1.5% (placebo 1.5%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg
alanine aminotransferase increased 2.8% (placebo 0%)
nasopharyngitis 2.8% (placebo 0%)
anaemia 0% (placebo 6.2%)
NCT01647516 · Phase 2 · registry result, not featured evidence
0.5 mg/1 mg
anaemia 5.4% (placebo 6.2%)
gamma-glutamyltransferase increased 5.4% (placebo 0%)
lymphocyte count decreased 5.4% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence
anaemia 7.3% (placebo 6.2%)
colitis ulcerative 7.3% (placebo 1.5%)
bronchitis 5.5% (placebo 0%)
NCT01647516 · Phase 2 · registry result, not featured evidence
60 mg once dailya
upper respiratory tract infection 8.6% (placebo 1.4%)
headache 5.7% (placebo 2.9%)
anaemia 2.9% (placebo 8.6%)
NCT05156125 · Phase 2 · monotherapy
show 4 more results
60 mg once daily
alanine aminotransferase increased 6.1% (placebo 1.4%)
aspartate animotransferase increased 6.1% (placebo 0%)
gamma-glutamyltransferase increased 6.1% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
60 mg once daily
lymphopenia 28.9% (placebo 0%)
nasopharyngitis 7.4% (placebo 4.3%)
upper respiratory tract infection 6.3% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
headache 6.8% (placebo 2.9%)
anaemia 5.5% (placebo 8.6%)
lymphopenia 1.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
gamma-glutamyltransferase increased 10.8% (placebo 1.4%)
alanine aminotransferase increased 5.4% (placebo 1.4%)
arthralgia 5.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ozanimod

Clinical Response 56.7% (n=67) vs 36.9% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
50.7% (n=67) vs 20% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
53.8% (n=65) vs 36.9% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
35.4% (n=65) vs 20% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
47.8% (n=429) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
52.6% (n=367) vs 25.9% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
60% (n=230) vs 39.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Endoscopic Improvement 34.3% (n=67) vs 12.3% (n=65) placebo @ 8wk1 mg
responder rate · % of participants
NCT01647516 · Phase 2 · registry result, not featured evidence
show 6 more results
32.8% (n=67) vs 12.3% (n=65) placebo @ 32wk1 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.7% (n=65) vs 12.3% (n=65) placebo @ 8wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
32.3% (n=65) vs 12.3% (n=65) placebo @ 32wk0.5 mg
NCT01647516 · Phase 2 · registry result, not featured evidence
27.3% (n=429) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
27.2% (n=367) vs 11.6% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
45.7% (n=230) vs 29% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Mucosal Healing 12.6% (n=429) vs 3.7% (n=216) placebo @ 10wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
show 2 more results
11.4% (n=367) vs 3.7% (n=216) placebo @ 10wk
NCT02435992 · Phase 3 · monotherapy
29.6% (n=230) vs 10.1% (n=69) placebo @ 52wk
NCT02435992 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 31.7% (n=230) vs 24.6% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Durable Clinical Remission 17.8% (n=230) vs 7.2% (n=69) placebo @ 52wk
responder rate · % of participants
NCT02435992 · Phase 3 · monotherapy
Clinical Remission 44% (n=266) vs 41.6% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
50.5% (n=266) vs 57.8% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50.9% (n=266) vs 59.4% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
54.7% (n=266) vs 39.1% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
54.5% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Clinical Response 77% (n=261) vs 81.8% (n=110) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
83.9% (n=261) vs 84.1% (n=110) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
87.6% (n=261) vs 89.6% (n=110) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
86.4% (n=261) vs 82.2% (n=110) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
90.1% (n=261) vs 74.4% (n=110) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Endoscopic Improvement 49.7% (n=290) vs 51.2% (n=121) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
41.4% (n=30) vs 51.2% (n=121) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
58.6% (n=290) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
50% (n=30) vs 60.6% (n=121) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
60.8% (n=290) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
57.7% (n=30) vs 61.1% (n=121) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=290) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.3% (n=30) vs 49.1% (n=121) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
60.9% (n=290) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 43.5% (n=121) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Corticosteroid-free Clinical Remission 38% (n=266) vs 40.7% (n=113) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 4 more results
41.6% (n=266) vs 52.2% (n=113) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
45.1% (n=266) vs 55.1% (n=113) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.3% (n=266) vs 37% (n=113) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
48.2% (n=266) vs 38.5% (n=113) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Histologic Remission 25.4% (n=276) vs 19.4% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
48.1% (n=30) vs 19.4% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
32.8% (n=276) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
26.7% (n=30) vs 22.6% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
32.4% (n=276) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
48% (n=30) vs 32.9% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
47.5% (n=276) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
62.5% (n=30) vs 42.9% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
56.1% (n=276) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 34.1% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Mucosal Healing 20.4% (n=276) vs 14.8% (n=108) placebo @ 46wk
responder rate · % of participants
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 9 more results
25.9% (n=30) vs 14.8% (n=108) placebo @ 46wk
NCT02531126 · Phase 3 · monotherapy
28% (n=276) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
20% (n=30) vs 19% (n=108) placebo @ 94wk
NCT02531126 · Phase 3 · monotherapy
27.4% (n=276) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
44% (n=30) vs 32.8% (n=108) placebo @ 142wk
NCT02531126 · Phase 3 · monotherapy
43.9% (n=276) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
37.5% (n=30) vs 32.7% (n=108) placebo @ 190wk
NCT02531126 · Phase 3 · monotherapy
46.3% (n=276) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
100% (n=30) vs 26.8% (n=108) placebo @ 238wk
NCT02531126 · Phase 3 · monotherapy
Complete Mayo -1.8 vs -3.5 placebo score @ 46wk
absolute change · score
Extension (open-label)
NCT02531126 · Phase 3 · monotherapy
show 6 more results
-2.2 vs -3.7 placebo score @ 94wk
NCT02531126 · Phase 3 · monotherapy
-2.5 vs -4.2 placebo score @ 142wk
NCT02531126 · Phase 3 · monotherapy
-2.6 vs -3.6 placebo score @ 190wk
NCT02531126 · Phase 3 · monotherapy
-2.9 vs -3.4 placebo score @ 238wk
NCT02531126 · Phase 3 · monotherapy
-3.9 vs -4.1 placebo score @ 286wk
NCT02531126 · Phase 3 · monotherapy
-4.4 vs -4.5 placebo score @ 334wk
NCT02531126 · Phase 3 · monotherapy

+ 5 further endpoints in the CSV export.

tamuzimod

Endoscopic Improvement 36.8% (n=68) vs 15.7% (n=70) placebo @ 13wk60 mg once daily
event count · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 25 Participants as posted
show 1 more result
32.4% (n=71) vs 15.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 23 Participants as posted
Symptomatic Remission 42.6% (n=68) vs 25.7% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
show 1 more result
40.8% (n=71) vs 25.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
Histologic Remission 19.1% (n=68) vs 7.1% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 13 Participants as posted
show 1 more result
28.2% (n=71) vs 7.1% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 20 Participants as posted
Endoscopic Improvement-Histologic Remission 10.3% (n=68) vs 0% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 7 Participants as posted
show 1 more result
19.7% (n=71) vs 0% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 14 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · tamuzimod's landscape